×

img Acces sibility Controls

Research Projects Banner

Research Projects

Development of Novel Purine Nucleoside-Quinoline Conjugates as Effective Inhibitors for Chikungunya and Dengue Viruses

Implementing Organization

Dr. B R Ambedkar National Institute of Technology (NIT), Jalandhar, Punjab
Principal Investigator
Dr. Rakesh Kumar
Dr. B R Ambedkar National Institute of Technology (NIT), Jalandhar, Punjab
CO-Principal Investigator
Prof. shailly Tomar
Indian Institute of Technology Roorkee, Uttarakhand, Roorkee (247667)

About

The re-emergence of vector-borne infections, such as Chikungunya and Dengue, poses a significant health and economic threat worldwide. India, being a densely populated country, is prone to infection outbreaks. The lack of an approved vaccine for these viruses makes the situation vulnerable. Quinoline, a privileged scaffold in medicinal chemistry, remains the preferred pharmacophore in antiviral drug design. Quinoline-derived antimalarial drug, chloroquine, has been reported to inhibit these viruses. Nucleoside analogs are another important class of broad-spectrum antivirals that have shown potency against these viruses. The conjugation of nucleoside scaffolds to bioactive molecules has shown to significantly improve their bioactivity. Novel quinoline-purine nucleoside conjugates (adenosine and deoxyadenosine) conjugates are proposed as effective CHIKV and DENV inhibitors. The study will use an environmentally friendly approach to access a library of novel adenosine and deoxyadenosine conjugates of quinoline N-oxides. Molecular docking studies will be performed with viral proteins to understand their interactions and assess structure activity relations for designing effective inhibitors. Antiviral activities will be assessed through cell-based antiviral assays using previously isolated strains.

Source

Source
science and Engineering Research Board (sERB), DsT
Funding Organization
Funding Organization
Anusandhan National Research Foundation (ANRF)
Quick Information
Area of Research
Life Sciences & Biotechnology
Focus Area
Medicinal Chemistry
Start Year
2024
End Year
2027
Sanction Amount
₹ 44.06 L
Status
Ongoing
Contact
rakeshccny@gmail.com
Output
No. of Research Paper
00
Technologies (If Any)
00
No. of PhD Produced
00
No. of Patents
Filed : 00
Grant : 00
Disclaimer: Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
arrowtop
Latest Updates
Loading…